The liver is the only organ in the body that can regenerate. However, some patients who suffer from liver elevation, surgery that remove an infectious part of the organ, have to have a transplant at the end because the renewal process does not work.
New Michigan State University study, published in the magazine Blood, shows that the blood-clotine protein fiberinogen can have the key why this happens.
"We found that a fibrinogen accumulates within the rest of the liver quickly after surgery and tells a plate so that they can act as first responders, triggering the earliest phase of regeneration," he said James Luyendyk, pathobiology teacher at Veterinary Medicine College. "But if fiberinogen or platelets have been stopped, regeneration will be delayed."
Plates are blood cells that help to form clots and to prevent bleeding. When they receive information from a fibrinogen, they act and build up in the remaining part of the liver to help restore them, increasing the chance of junior full recovery and successful recovery.
Using samples of patients experiencing liver elevation and a similar model in mice, Luyendyk and his team realized that when a low fibrinogen reduced the number of plate in the liver.
"This shows that fibrinogen deposits are extremely important and have a direct impact on regeneration in both people and men," said Luyendyk.
According to Dafna Groeneveld, co-author Luyendyk and a research post-doctoral research link in his laboratory, their perception shows that fiberinogen levels may also be a predictive indication for doctors.
"Measuring this protein in junior extraction patients can help us to determine in advance whether the organ will regenerate successfully or if it becomes obsolete," he said.
This could lead to new treatments that would help doctors correct the low levels of protein using fibrinogen concentrations that can be administered during the operation.
"This type of treatment has not been proven in liver extraction patients again," said Luyendyk. "But once we will identify exactly how fibrinogen works in the regeneration process and testing potential therapeutic in mice, it could eventually provide the test that we need to bring work to the clinic and improving patient outcomes. "